Radhakrishnan Ramchandren Selected Research

Brentuximab Vedotin

1/2022	Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
1/2022	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
1/2022	Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.
12/2021	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
6/2021	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
1/2021	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
1/2020	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
1/2019	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
1/2018	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
1/2018	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Radhakrishnan Ramchandren Research Topics

Disease

22	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 06/2012
9	Neoplasms (Cancer) 01/2021 - 12/2013
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2021 - 10/2013
4	Neutropenia 01/2021 - 01/2018
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020 - 01/2019
4	Disease Progression 10/2019 - 10/2013
4	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 12/2017 - 06/2012
3	B-Cell Lymphoma (Lymphoma, B Cell) 10/2021 - 01/2020
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 03/2014
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2020 - 12/2014
2	Febrile Neutropenia 01/2022 - 01/2018
2	Pneumonia (Pneumonitis) 01/2021 - 02/2019
2	Lymphoma (Lymphomas) 01/2020 - 06/2012
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2020 - 01/2020
2	Exanthema (Rash) 10/2019 - 01/2018
2	Anemia 10/2019 - 01/2018
2	Hematologic Neoplasms (Hematological Malignancy) 03/2014 - 08/2013
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Nausea 12/2021
1	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/2020
1	Chemical and Drug Induced Liver Injury 01/2020
1	Hepatitis 01/2020
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 10/2019
1	Acute Kidney Injury (Acute Renal Failure) 02/2019
1	Respiratory Insufficiency (Respiratory Failure) 01/2019
1	Sepsis (Septicemia) 01/2019
1	Fatigue 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Stomatitis 01/2018
1	Renal Cell Carcinoma (Grawitz Tumor) 12/2014
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2009

Drug/Important Bio-Agent (IBA)

18	Brentuximab VedotinIBA 01/2022 - 06/2012
6	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2018
6	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 08/2013
5	Dacarbazine (DIC)FDA LinkGeneric 01/2022 - 01/2018
5	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 01/2018
5	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022 - 01/2018
4	NivolumabIBA 12/2021 - 01/2018
4	Rituximab (Mabthera)FDA Link 01/2020 - 01/2018
3	ibrutinibIBA 10/2021 - 01/2019
3	Pharmaceutical PreparationsIBA 10/2018 - 08/2013
3	Lenalidomide (CC 5013)FDA Link 10/2017 - 10/2013
2	pembrolizumabIBA 01/2022 - 01/2021
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 01/2018
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2021 - 10/2019
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 10/2021 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2020
2	Monoclonal AntibodiesIBA 01/2021 - 10/2019
2	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 01/2019
2	Immune Checkpoint InhibitorsIBA 01/2020 - 02/2019
2	Ifosfamide FDA LinkGeneric 01/2020 - 01/2019
2	LigandsIBA 10/2018 - 01/2018
1	venetoclaxIBA 10/2021
1	Histone Deacetylases (Histone Deacetylase)IBA 10/2021
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	fimepinostatIBA 10/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020
1	durvalumabIBA 01/2020
1	urelumabIBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2020
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020
1	PlatinumIBA 01/2020
1	Prednisone (Sone)FDA LinkGeneric 01/2020
1	Vincristine (Oncovin)FDA LinkGeneric 01/2020
1	tributyl phosphate (TBP)IBA 01/2020
1	Aurora Kinase AIBA 10/2019
1	MLN 8237IBA 10/2019
1	Aspartic Acid (Aspartate)FDA Link 01/2019
1	itacitinibIBA 01/2019
1	Carboplatin (JM8)FDA LinkGeneric 01/2019
1	Alanine Transaminase (SGPT)IBA 01/2019
1	Janus Kinase 1IBA 01/2019
1	parsaclisibIBA 01/2019
1	Lipase (Acid Lipase)FDA Link 10/2018
1	Inotuzumab OzogamicinIBA 01/2018
1	Everolimus FDA Link 01/2018
1	B7-H1 AntigenIBA 01/2018
1	Bortezomib (Velcade)FDA Link 10/2013
1	Dasatinib (BMS 354825)FDA Link 01/2009
1	Imatinib Mesylate (Gleevec)FDA Link 01/2009

Therapy/Procedure

14	Therapeutics 01/2022 - 01/2009
9	Drug Therapy (Chemotherapy) 06/2021 - 01/2018
8	Stem Cell Transplantation 01/2022 - 06/2012
3	Salvage Therapy 12/2021 - 01/2018
1	Transplantation 01/2022
1	Homologous Transplantation 01/2021
1	Nephrectomy 02/2019
1	Cell Transplantation 10/2018
1	Intravenous Administration 01/2016
1	Retreatment 03/2014